{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.045","upperLimit":"0.229","value":"0.105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Overall Response Rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) as best response on treatment based on RECIST v1.1 criteria.","dispersionType":"80% Confidence Interval","groups":[{"description":"Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.\n\nTremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.\n\nDurvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.","id":"OG000","title":"Tremelimumab + Durvalumab"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"ORR was assessed every 8 weeks from Cycle 1 Day 1 until date of documented disease progression or death. The median treatment duration is 1.91 months with range (0.00 months - 23.46 months).","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"proportion of paticipants"}